Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-05-03
2011-05-03
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S133000
Reexamination Certificate
active
07935700
ABSTRACT:
A compound represented by the formula (1)wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.
REFERENCES:
patent: 4870074 (1989-09-01), Kon et al.
patent: 2004/0014775 (2004-01-01), Du Bois et al.
patent: 2004/0058923 (2004-03-01), Ancliff et al.
patent: 1 389 616 (2004-02-01), None
patent: 63-264467 (1988-11-01), None
patent: 2004-509952 (2004-04-01), None
patent: 00/53600 (2000-09-01), None
patent: 03/082294 (2003-10-01), None
patent: 2004/004731 (2004-01-01), None
Byrn et al., Solid-State Chemistry of Drugs, Second Edition, 1999, pp. 233-247.
Registry No. 852165-28-7, Jun. 13, 2005.
Pease et al., Expert Opin. Ther. Patents (2009) 19(1), 39-58.
Heidi Heath et al., “Chemokine Receptor Usage by Human Eosinophils”, J. Clin. Invest., vol. 99, No. 2, pp. 178-184, Jan. 1997.
Hiroshi Ochi et al., “T Helper Cell Type 2 Cytokine-mediated Comitogenic Responses and CCR3 Expression During Differentiation of Human Mast Cells In Vitro”, J. Exp. Med., vol. 190, No. 2, pp. 267-280, Jul. 19, 1999.
Mariagrazia Uguccioni et al., “High Expression of the Chemokine Receptor CCR3 in Human Blood Basophils”, J. Clin. Invest., vol. 100, No. 5, pp. 1137-1143, Sep. 1997.
Federica Sallusto et al., “Selective Expression of the Eotaxin Receptor CCR3 by Human T Helper 2 Cells”, Science, vol. 277, 5334, pp. 2005-2007, Sep. 26, 1997.
Phillip M. Murphy et al., “International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors”, Pharmacological Reviews, vol. 52, No. 1, pp. 145-176, 2000.
Weilie Ma et al. “CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation”, The Journal of Clinical Investigation, vol. 109, No. 5, pp. 621-628, Mar. 2002.
Frode L. Jahnsen et al., “Glucocorticosteroids Inhibit mRNA Expression for Eotaxin, Eotaxin-2, and Monocyte-Chemotactic Protein-4 in Human Airway Inflammation with Eosinophilia”, The Journal of Immunology, vol. 163, No. 3, pp. 1545-1551, 1999.
Kenneth J. Katschke, Jr. et al., “Differential Expression of Chemokine Receptors on Peripheral Blood, Synovial Fluid, and Synovial Tissue Monocytes/Macrophages in Rheumatoid Arthritis”, Arthritis & Rheumatism, vol. 44, No. 5, pp. 1022-1032, May 2001.
Supplementary European Search Report issued Sep. 9, 2010 in European Application No. 05 78 3689 corresponding to the present US Application.
Hamada Maiko
Higashi Hidemitsu
Kobayashi Fujio
Matsuura Mamoru
Takeda Shuzo
Anderson Rebecca L
Mitsubishi Tanabe Pharma Corporation
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Morpholine compound does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Morpholine compound, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Morpholine compound will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2662495